Berkeley Heights, NJ, May 4, 2004 -
Genta Incorporated (Nasdaq: GNTA) will host a conference call on
Wednesday, May 5, 2004. Dr. Raymond P. Warrell, Jr., Genta's Chief
Executive Officer, will host the conference call at 5:00 PM
EDT.
The conference call can be accessed live as follows:
U.S./Canada: Dial (877) 634-8606, reference Genta Incorporated.
International: Dial (706) 679-3140, reference Genta
Incorporated.
About Genta
Genta Incorporated is a pharmaceutical company with a diversified
product portfolio that is focused on delivering innovative products
for the treatment of patients with cancer. The Company's research
platform is anchored by two major programs that center on
oligonucleotides (RNA and DNA-based medicines) and small molecules.
Genasense
TM
(oblimersen sodium) Injection, the Company's lead compound from its
oligonucleotide program, is being developed with Aventis and is
currently undergoing late-stage, Phase 3 clinical testing. The
leading drug in Genta's small molecule program is Ganite® (gallium
nitrate injection), which the Company is exclusively marketing in
the U.S. for treatment of patients with cancer-related
hypercalcemia that is resistant to hydration. For more information
about Genta, please visit our website at:
http://www.genta.com/
.
This press release and the conference call to follow contain
forward-looking statements with respect to business conducted by
Genta Incorporated. By their nature, forward-looking statements
and forecasts involve risks and uncertainties because they relate
to events and depend on circumstances that will occur in the
future. There are a number of factors that could cause actual
results and developments to differ materially. For a discussion
of those risks and uncertainties, please see the Company's Annual
Report/Form 10-K for 2003.
SOURCE: Genta Incorporated
